Immunotherapy: A Novel Approach to Fighting Drug-Resistant Bacteria

Video

Marcos Pires, PhD, assistant professor at Lehigh University, explains the inspiration behind his team’s research in immunotherapy as a new way to fight bacterial infection.

Marcos Pires, PhD, assistant professor at Lehigh University, explains the inspiration behind his team’s research in immunotherapy as a new way to fight bacterial infection.

Interview Transcript (slightly modified for readability)

“We started studying alternative methods to go after bacteria because we are at a point right now where a lot of the current antibiotics that are FDA-approved, either don’t work anymore or they work a lot less than they used to. It’s projected that in the near future, [last resort antibiotics] may stop working and when that time comes, the way that we know modern medicine can change quite a bit. We’re used to bacterial infections being something that’s simple to treat, usually with a short course of antibiotics, which is usually very cheap. When the time comes that a lot of the bacteria become resistant to those antibiotics, infections, even simple infections, can become life threatening.

On top of that, there’s the complication that a lot of other medical procedures also rely on antibiotics to be able to perform successfully. This includes: organ transplantation, cancer chemotherapy, invasive operations, and in the backbone of a lot of these procedures, antibiotics represent a way to prevent infection. In that case, it’s not necessarily going into curing infection but just keep[ing infection] at bay.

We’re interested in finding ways that we can try to slow down the emergence of drug-resistant, or at least the prevalence of drug-resistant bacteria, by trying to come up with new antibiotics. Now, the problem has been that it’s easier said than done. It has been tried; it has been tried for several decades, and this includes billions of dollars in a very dedicated effort on the part of pharmaceutical companies, and yet, it’s been difficult to come up with new antibiotics.

Given our resources, we tried to come up with a way that was unique, and that’s where the story started for us. We started to try and come up with a way that would, in essence, give the same end-result, which is the destruction, or the killing of bacteria, but perhaps in an untraditional way. Traditional antibiotics, what they do is they go in and disrupt a critical or essential process in bacteria. So, we decided to at least start thinking about other ways that we can get the same [end] product or the same result but without a traditional antibiotic; that was the beginning of our research.”

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.